Genetic Study of Families With High Frequency of Hodgkin Lymphoma
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/15/2018 |
| Start Date: | August 17, 2016 |
| End Date: | February 27, 2018 |
Hodgkin lymphoma (HL) is a relatively rare disorder with known familiar aggregation (i.e. HL
in more than one child, or parent and child). Because affected individuals in familial HL are
genetically related, the existence of such families has long been considered as evidence in
support of a genetic basis of HL susceptibility. However, it is largely unknown which genetic
variations are responsible for recurring HL in families. Because the effects of genetic
variants are likely to be strong in familial HL, identification of such variations will
potentially reveal biological pathways critical to the pathogenesis of HL.
PRIMARY OBJECTIVE:
- To perform genome-wide sequencing of families with recurring Hodgkin lymphoma cases
(affected as well as non-affected family members) to identify potential disease-causing
germline genetic variations.
SECONDARY OBJECTIVE:
- To describe demographic and clinical features of the affected families.
in more than one child, or parent and child). Because affected individuals in familial HL are
genetically related, the existence of such families has long been considered as evidence in
support of a genetic basis of HL susceptibility. However, it is largely unknown which genetic
variations are responsible for recurring HL in families. Because the effects of genetic
variants are likely to be strong in familial HL, identification of such variations will
potentially reveal biological pathways critical to the pathogenesis of HL.
PRIMARY OBJECTIVE:
- To perform genome-wide sequencing of families with recurring Hodgkin lymphoma cases
(affected as well as non-affected family members) to identify potential disease-causing
germline genetic variations.
SECONDARY OBJECTIVE:
- To describe demographic and clinical features of the affected families.
This study entails a clinical interview and submission of a peripheral blood or saliva sample
for non-tumor DNA. Participants diagnosed with HL at outside institutions will be requested
to sign a release form to allow the outside institution to send their pathology report
confirming their HL diagnosis. If available, previously banked tumor tissue samples will be
utilized to assess genetic alterations related to HL. Detailed history will be obtained
(e.g., demographics, environmental exposures, cancer risk factors, and family pedigree) to
facilitate the analysis of phenotype-genotype correlations, taking into account potential
confounding factors.
Investigators will examine the germline and possibly the tumor DNA of each individual
participant and use the data from all participants to determine if a gene change is related
to HL.
for non-tumor DNA. Participants diagnosed with HL at outside institutions will be requested
to sign a release form to allow the outside institution to send their pathology report
confirming their HL diagnosis. If available, previously banked tumor tissue samples will be
utilized to assess genetic alterations related to HL. Detailed history will be obtained
(e.g., demographics, environmental exposures, cancer risk factors, and family pedigree) to
facilitate the analysis of phenotype-genotype correlations, taking into account potential
confounding factors.
Investigators will examine the germline and possibly the tumor DNA of each individual
participant and use the data from all participants to determine if a gene change is related
to HL.
Inclusion Criteria:
- Patient with HL diagnosed ≤ 21 years of age with a first-degree relative also
diagnosed with HL.
- Family members of the patient, either affected or unaffected by a malignancy who agree
to participate in the study.
- Research participant or legal guardian, as appropriate, must provide informed consent
for this protocol.
Exclusion Criteria:
- Inability or unwillingness of research participant or legal guardian/representative to
give written informed consent.
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Jamie Flerlage, MD
Phone: 866-278-5835
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
